PFE – Pfizer Inc.
Pfizer, Inc.PFE
$26.30Name : Pfizer, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $149,041,840,128.00
EPSttm : 1.41
Pfizer, Inc.
$26.30
1.54%$0.4Float Short %
1.3
Margin Of Safety %
27
Put/Call OI Ratio
0.77
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
0.11
Price
26.3
Target Price
30.79
Analyst Recom
2.29
Performance Q
5.79
Relative Volume
1.36
Beta
0.58
Ticker: PFE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | PFE | 26.42 | 0.88 | 0.42 | 2691914 |
| 2025-01-24 | PFE | 26.08 | 0.93 | 0.53 | 2791599 |
| 2025-01-27 | PFE | 26.85 | 0.91 | 0.35 | 2749310 |
| 2025-01-28 | PFE | 26.75 | 0.91 | 0.35 | 2806094 |
| 2025-01-29 | PFE | 26.61 | 0.90 | 1.12 | 2832825 |
| 2025-01-30 | PFE | 26.91 | 0.91 | 1.23 | 2867983 |
| 2025-01-31 | PFE | 26.52 | 0.93 | 0.96 | 2926862 |
| 2025-02-03 | PFE | 26.27 | 0.95 | 0.69 | 2809972 |
| 2025-02-04 | PFE | 25.86 | 0.92 | 0.39 | 2881294 |
| 2025-02-05 | PFE | 26.49 | 0.89 | 0.38 | 2986446 |
| 2025-02-06 | PFE | 25.83 | 0.86 | 0.46 | 3050610 |
| 2025-02-07 | PFE | 25.75 | 0.84 | 0.39 | 3089741 |
| 2025-02-10 | PFE | 25.87 | 0.85 | 0.40 | 2937858 |
| 2025-02-11 | PFE | 25.46 | 0.83 | 0.28 | 3024489 |
| 2025-02-12 | PFE | 25.47 | 0.83 | 0.21 | 3064033 |
| 2025-02-13 | PFE | 25.64 | 0.80 | 0.64 | 3125926 |
| 2025-02-14 | PFE | 25.53 | 0.79 | 0.32 | 3127236 |
| 2025-02-18 | PFE | 25.56 | 0.81 | 0.29 | 3050346 |
| 2025-02-19 | PFE | 25.87 | 0.78 | 0.31 | 3153616 |
| 2025-02-20 | PFE | 25.87 | 0.77 | 0.70 | 3185936 |
| 2025-02-21 | PFE | 26.27 | 0.77 | 0.17 | 3232652 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | PFE | 26.44 | 361.6 | 13933.5 | 2.93 |
| 2025-01-24 | PFE | 26.09 | 361.6 | 13736.1 | 2.93 |
| 2025-01-27 | PFE | 26.89 | 361.6 | 14398.6 | 2.93 |
| 2025-01-28 | PFE | 26.75 | 361.6 | 13873.1 | 2.93 |
| 2025-01-29 | PFE | 26.62 | 361.6 | 13614.3 | 2.93 |
| 2025-01-30 | PFE | 26.91 | 361.6 | 13850.7 | 2.93 |
| 2025-01-31 | PFE | 26.51 | 361.6 | 13463.6 | 2.93 |
| 2025-02-03 | PFE | 26.20 | 360.3 | 13506.4 | 2.93 |
| 2025-02-04 | PFE | 25.87 | 359.2 | 13499.1 | 2.93 |
| 2025-02-05 | PFE | 26.50 | 359.2 | 14084.2 | 2.93 |
| 2025-02-06 | PFE | 25.82 | 359.2 | 13336.2 | 2.93 |
| 2025-02-07 | PFE | 25.74 | 359.2 | 14016.5 | 2.94 |
| 2025-02-10 | PFE | 25.87 | 359.2 | 14145.8 | 2.94 |
| 2025-02-11 | PFE | 25.53 | 359.2 | 13870.3 | 2.95 |
| 2025-02-12 | PFE | 25.47 | 359.2 | 14034.0 | 2.95 |
| 2025-02-13 | PFE | 25.64 | 359.2 | 14170.0 | 2.95 |
| 2025-02-14 | PFE | 25.53 | 359.2 | 14004.5 | 2.95 |
| 2025-02-18 | PFE | 25.56 | -13.5 | 14087.2 | 2.95 |
| 2025-02-19 | PFE | 25.89 | -13.5 | 14264.5 | 2.95 |
| 2025-02-20 | PFE | 25.90 | -13.5 | 14075.3 | 2.95 |
| 2025-02-21 | PFE | 26.30 | -13.5 | 14303.6 | 2.95 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | PFE | -0.24 | 0.12 | 1.34 |
| 2025-01-24 | PFE | -0.24 | 0.12 | 1.34 |
| 2025-01-27 | PFE | -0.24 | -0.26 | 1.34 |
| 2025-01-28 | PFE | -0.18 | -0.26 | 1.62 |
| 2025-01-29 | PFE | -0.18 | -0.26 | 1.62 |
| 2025-01-30 | PFE | -0.18 | -0.26 | 1.62 |
| 2025-01-31 | PFE | -0.18 | -0.26 | 1.62 |
| 2025-02-03 | PFE | -0.18 | -0.29 | 1.62 |
| 2025-02-04 | PFE | -0.15 | -0.29 | 1.62 |
| 2025-02-05 | PFE | -0.18 | -0.29 | 1.62 |
| 2025-02-06 | PFE | -0.18 | -0.29 | 1.62 |
| 2025-02-07 | PFE | -0.18 | -0.29 | 1.62 |
| 2025-02-10 | PFE | -0.18 | -0.26 | 1.62 |
| 2025-02-11 | PFE | -0.03 | -0.26 | 1.62 |
| 2025-02-12 | PFE | -0.03 | -0.26 | 1.30 |
| 2025-02-13 | PFE | -0.03 | -0.26 | 1.30 |
| 2025-02-14 | PFE | 0.91 | -0.26 | 1.30 |
| 2025-02-18 | PFE | 0.91 | 0.12 | 1.30 |
| 2025-02-19 | PFE | 0.36 | 0.12 | 1.30 |
| 2025-02-20 | PFE | 0.36 | 0.12 | 1.30 |
| 2025-02-21 | PFE | 0.40 | 0.12 | 1.30 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.71
Avg. EPS Est. Next Quarter
0.57
Insider Transactions
0.4
Institutional Transactions
0.12
Beta
0.58
Average Sales Estimate Current Quarter
14374
Average Sales Estimate Next Quarter
13539
Fair Value
33.5
Quality Score
72
Growth Score
61
Sentiment Score
73
Actual DrawDown %
57.4
Max Drawdown 5-Year %
-54.8
Target Price
30.79
P/E
18.68
Forward P/E
8.63
PEG
P/S
2.34
P/B
1.61
P/Free Cash Flow
18.12
EPS
1.41
Average EPS Est. Cur. Y
2.95
EPS Next Y. (Est.)
3.06
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
12.62
Relative Volume
1.36
Return on Equity vs Sector %
-14.6
Return on Equity vs Industry %
-22.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
14303.6
Pfizer, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees:
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
stock quote shares PFE – Pfizer Inc. Stock Price stock today
news today PFE – Pfizer Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PFE – Pfizer Inc. yahoo finance google finance
stock history PFE – Pfizer Inc. invest stock market
stock prices PFE premarket after hours
ticker PFE fair value insiders trading